SEL24 is a Selvita-developed first-in-class dual PIM/FLT3 kinase inhibitor with a unique activity profile in oral formulation. It is intended for the treatment of patients with relapsed/refractory (R/R) AML. The major goal for treatment of R/R AML is to achieve remission or to significantly prolong life, with acceptable quality.
In March 2017, the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML).
On March 28, 2017, Selvita S.A. and Berlin-Chemie Menarini, a company of the Menarini Group, announced that both companies have entered into a global license agreement for SEL24, a dual PIM/FLT3 inhibitor currently in Phase I/II trials in acute myeloid leukemia (AML) patients.
According to the agreement, Selvita will grant Menarini Group an exclusive license to further research, develop, manufacture and commercialize SEL24 worldwide. Under the terms of the agreement, Selvita will receive an upfront payment, and will be eligible to receive milestone payments and royalty on future sales.